{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:01:24Z","timestamp":1795017684749,"version":"4.10.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite global malaria control efforts, malaria continues to cause approximately 241\u2013249 million cases and over 600,000 deaths annually. Ivermectin, a broad-spectrum antiparasitic drug with endectocidal activity against mosquitoes feeding on treated hosts, has been proposed as a potential malaria vector-control intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the effectiveness of ivermectin in reducing malaria transmission outcomes in adult populations, including malaria incidence, prevalence, mosquito mortality, and safety outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA 2020 guidelines, we included randomized controlled trials (RCTs) and cluster-RCTs evaluating ivermectin compared with placebo, standard care, or non-ivermectin controls in adult populations. Outcomes included malaria incidence, prevalence, mosquito mortality, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten randomized trials involving 63,192 participants were included. Community-level analyses showed no significant reduction in malaria prevalence, with very wide confidence intervals reflecting substantial imprecision. Entomological trials demonstrated increased mosquito mortality following ivermectin exposure (RR 1.89; 95% CI 1.26\u20132.83), although heterogeneity was substantial (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009&gt;\u200997%). Across studies, ivermectin was generally well tolerated, with no significant increase in adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence does not demonstrate consistent reductions in malaria incidence or prevalence with ivermectin administration, although laboratory and experimental studies suggest mosquitocidal effects. Further large, well-designed cluster-randomized trials are required to determine whether ivermectin can contribute to malaria control strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-026-05895-z","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:06:31Z","timestamp":1774944391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of ivermectin for malaria vector control: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Shrouk","family":"Ramadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Talkhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dua\u2019a","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Noureldeen","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Bin","family":"Sahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Hamzeh","family":"Hamzeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat","family":"Alfaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elnouty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1366-2375","authenticated-orcid":false,"given":"Mohammed Hammad Jaber","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"5895_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parepi.2023.e00295","volume":"21","author":"A Alemayehu","year":"2023","unstructured":"Alemayehu A. Biology and epidemiology of Plasmodium falciparum and Plasmodium vivax gametocyte carriage: implication for malaria control and elimination. Parasite Epidemiol Control. 2023;21:e00295.","journal-title":"Parasite Epidemiol Control"},{"issue":"2024","key":"5895_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/6619010","volume":"23","author":"M Balmith","year":"2024","unstructured":"Balmith M, Basson C, Brand SJ. The Malaria Burden: A South African Perspective. J Trop Med. 2024;23(2024):1\u201317.","journal-title":"J Trop Med"},{"issue":"1","key":"5895_CR3","doi-asserted-by":"publisher","first-page":"16734","DOI":"10.1038\/s41598-024-67452-5","volume":"14","author":"OC Villena","year":"2024","unstructured":"Villena OC, Arab A, Lippi CA, Ryan SJ, Johnson LR. Influence of environmental, geographic, socio-demographic, and epidemiological factors on presence of malaria at the community level in two continents. Sci Rep. 2024;14(1):16734.","journal-title":"Sci Rep"},{"issue":"11","key":"5895_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa2026330","volume":"385","author":"D Chandramohan","year":"2021","unstructured":"Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, et al. Seasonal malaria vaccination with or without seasonal malaria chemoprevention. N Engl J Med. 2021;385(11):1005\u201317.","journal-title":"N Engl J Med"},{"issue":"2","key":"5895_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-091569","volume":"15","author":"G Kombate","year":"2025","unstructured":"Kombate G, Djalogue L, Ngangue P, Soubeiga KAM, Grobbee DE, van der Sande M. Integrated malaria vector control strategies and their effectiveness in sub-Saharan Africa: a systematic review protocol for interventional studies. BMJ Open. 2025;15(2):e091569.","journal-title":"BMJ Open"},{"issue":"1","key":"5895_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12936-021-03943-4","volume":"20","author":"A Monroe","year":"2021","unstructured":"Monroe A, Moore S, Olapeju B, Merritt AP, Okumu F. Unlocking the human factor to increase effectiveness and sustainability of malaria vector control. Malar J. 2021;20(1):404.","journal-title":"Malar J"},{"issue":"2","key":"5895_CR7","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1093\/infdis\/jiaa582","volume":"223","author":"MH Rodriguez","year":"2021","unstructured":"Rodriguez MH. Residual malaria: limitations of current vector control strategies to eliminate transmission in residual foci. J Infect Dis. 2021;223(2):S55-60.","journal-title":"J Infect Dis"},{"key":"5895_CR8","doi-asserted-by":"crossref","unstructured":"malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication. PLoS Med. 2017;14(11):e1002450.","DOI":"10.1371\/journal.pmed.1002450"},{"issue":"3","key":"5895_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s44197-024-00228-2","volume":"14","author":"J Li","year":"2024","unstructured":"Li J, Docile HJ, Fisher D, Pronyuk K, Zhao L. Current status of malaria control and elimination in Africa: epidemiology, diagnosis, treatment, progress and challenges. J Epidemiol Glob Health. 2024;14(3):561\u201379.","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"5895_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006020","volume":"12","author":"J Mu\u00f1oz","year":"2018","unstructured":"Mu\u00f1oz J, Ballester MR, Antonijoan RM, Gich I, Rodr\u00edguez M, Colli E, et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis. 2018;12(1):e0006020.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"5895_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","volume":"16","author":"C Chaccour","year":"2017","unstructured":"Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J. 2017;16(1):161.","journal-title":"Malar J"},{"issue":"4","key":"5895_CR12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa2411262","volume":"393","author":"C Chaccour","year":"2025","unstructured":"Chaccour C, Maia M, Kariuki M, Ruiz-Castillo P, Wanjiku C, Kasiwa L, et al. Ivermectin to control malaria \u2014 a cluster-randomized trial. N Engl J Med. 2025;393(4):362\u201375.","journal-title":"N Engl J Med"},{"issue":"7","key":"5895_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1473-3099(24)00751-5","volume":"25","author":"AF Som\u00e9","year":"2025","unstructured":"Som\u00e9 AF, Som\u00e9 A, Sougu\u00e9 E, Ou\u00e9draogo COW, Da O, Dah SR, et al. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. Lancet Infect Dis. 2025;25(7):737\u201350.","journal-title":"Lancet Infect Dis"},{"key":"5895_CR14","first-page":"6","volume":"2021","author":"DK de Souza","year":"2021","unstructured":"de Souza DK, Thomas R, Bradley J, Leyrat C, Boakye DA, Okebe J. Ivermectin treatment in humans for reducing malaria transmission. Cochrane Database System Rev. 2021;2021:6.","journal-title":"Cochrane Database System Rev"},{"key":"5895_CR15","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editors. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019."},{"key":"5895_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:n71.","journal-title":"BMJ"},{"key":"5895_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28:l4898.","journal-title":"BMJ"},{"issue":"1","key":"5895_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1086\/653208","volume":"202","author":"C Chaccour","year":"2010","unstructured":"Chaccour C, Lines J, Whitty CJM. Effect of Ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202(1):113\u20136.","journal-title":"J Infect Dis"},{"issue":"4","key":"5895_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1473-3099(21)00557-0","volume":"22","author":"ED Dabira","year":"2022","unstructured":"Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, et al. Mass drug administration of Ivermectin and Dihydroartemisinin\u2013piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2022;22(4):519\u201328.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"5895_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1473-3099(24)00580-2","volume":"25","author":"H Hutchins","year":"2025","unstructured":"Hutchins H, Pretorius E, Bradley J, Teixeira da Silva E, Vasileva H, Ndiath MO, et al. Adjunctive ivermectin mass drug administration for malaria control on the Bijagos Archipelago of Guinea-Bissau (MATAMAL): a quadruple-blinded, cluster-randomised, placebo-controlled trial. Lancet Infect Dis. 2025;25(4):424\u201334.","journal-title":"Lancet Infect Dis"},{"key":"5895_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103632","volume":"90","author":"C Chaccour","year":"2025","unstructured":"Chaccour C, Nicolas P, Martinho S, Mundaca H, Elobolobo E, Ruiz-Castillo P, et al. Ivermectin to reduce malaria transmission\u2013 safety and efficacy results from the BOHEMIA cluster randomized trial in Mozambique. EClinicalMedicine. 2025;90:103632.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"5895_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/cid\/ciu797","volume":"60","author":"AL Ouedraogo","year":"2015","unstructured":"Ouedraogo AL, Bastiaens GJH, Tiono AB, Guelbeogo WM, Kobylinski KC, Ouedraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized. Clin Trial Clin Infect Dis. 2015;60(3):357\u201365.","journal-title":"Clin Trial Clin Infect Dis"},{"issue":"3","key":"5895_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/tmi.13357","volume":"25","author":"WG Metzger","year":"2020","unstructured":"Metzger WG, Theurer A, Pfleiderer A, Molnar Z, Maih\u00f6fer-Braatting D, Bissinger AL, et al. Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. Tropical Med Int Health. 2020;25(3):380\u20136.","journal-title":"Tropical Med Int Health"},{"issue":"6","key":"5895_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","volume":"18","author":"MR Smit","year":"2018","unstructured":"Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abong\u2019o BO, Chen T, et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018;18(6):615\u201326.","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"5895_CR25","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/cid\/ciy1063","volume":"69","author":"MR Smit","year":"2019","unstructured":"Smit MR, Ochomo EO, Aljayyoussi G, Kwambai TK, Abongo BO, Bousema T, et al. Human direct skin feeding versus membrane feeding to assess the mosquitocidal efficacy of high-dose ivermectin (IVERMAL Trial). Clin Infect Dis. 2019;69(7):1112\u20139.","journal-title":"Clin Infect Dis"},{"key":"5895_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104814","volume":"97","author":"D Ekoka Mbassi","year":"2023","unstructured":"Ekoka Mbassi D, Mombo-Ngoma G, Held J, Okwu DG, Ndzebe-Ndoumba W, Kalkman LC, et al. Efficacy and safety of Ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults \u2013 a pilot randomized, double-blind, placebo-controlled single-centre phase Ib\/IIa clinical trial. EBioMedicine. 2023;97:104814.","journal-title":"EBioMedicine"},{"issue":"10180","key":"5895_CR27","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(18)32321-3","volume":"393","author":"BD Foy","year":"2019","unstructured":"Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, et al. Efficacy and risk of harms of repeat Ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019;393(10180):1517\u201326.","journal-title":"Lancet"},{"issue":"2","key":"5895_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97\u2013111.","journal-title":"Res Synth Methods"},{"issue":"4","key":"5895_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(19)30633-4","volume":"20","author":"HC Slater","year":"2020","unstructured":"Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infect Dis. 2020;20(4):498\u2013508.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"5895_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002455","volume":"14","author":"Elimination malERA RCP on T for M","year":"2017","unstructured":"Elimination malERA RCP on T for M. malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication. PLoS Med. 2017;14(11):e1002455.","journal-title":"PLoS Med"},{"issue":"2 Suppl","key":"5895_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.19-0620","volume":"102","author":"Roadmappers TI","year":"2020","unstructured":"Roadmappers TI. A roadmap for the development of ivermectin as a complementary malaria vector control tool. Am J Trop Med Hyg. 2020;102(2 Suppl):3.","journal-title":"Am J Trop Med Hyg"},{"key":"5895_CR32","unstructured":"WHO. WHO Preferred Product Characteristics (PPC) for Malaria Vaccines WHO Preferred Product Characteristics (PPC) for Malaria Vaccines. 2014. p.1\u201327."},{"issue":"1","key":"5895_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03732-z","volume":"20","author":"A Fehr","year":"2021","unstructured":"Fehr A, Nieto-Sanchez C, Muela J, et al. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia. Malar J. 2021;20(1):198.","journal-title":"Malar J"},{"issue":"1","key":"5895_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-024-06294-6","volume":"17","author":"P Khemrattrakool","year":"2024","unstructured":"Khemrattrakool P, Hongsuwong T, Tipthara P, et al. Impact of ivermectin components on Anopheles dirus and Anopheles minimus mosquito survival. Parasit Vectors. 2024;17(1):224.","journal-title":"Parasit Vectors"},{"issue":"1","key":"5895_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-016-1417-5","volume":"9","author":"YA Derua","year":"2016","unstructured":"Derua YA, Malongo BB, Simonsen PE. Effect of ivermectin on the larvae of Anopheles gambiae and Culex quinquefasciatus. Parasit Vectors. 2016;9(1):131.","journal-title":"Parasit Vectors"},{"key":"5895_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpeds.2023.100085","volume":"6","author":"R Ranjha","year":"2023","unstructured":"Ranjha R, Singh K, Baharia RK, Mohan M, Anvikar AR, Bharti PK. Age-specific malaria vulnerability and transmission reservoir among children. Glob Pediatr Health. 2023;6:100085.","journal-title":"Glob Pediatr Health"},{"issue":"1","key":"5895_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3319-y","volume":"18","author":"P Selvaraj","year":"2018","unstructured":"Selvaraj P, Wenger EA, Gerardin J. Seasonality and heterogeneity of malaria transmission determine success of interventions in high-endemic settings: a modeling study. BMC Infect Dis. 2018;18(1):413.","journal-title":"BMC Infect Dis"},{"key":"5895_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1126\/scitranslmed.aag2374","volume":"8","author":"AM Bellinger","year":"2016","unstructured":"Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, et al. Oral, ultra\u2013long-lasting drug delivery: Application toward malaria elimination goals. Sci Transl Med. 2016;8:365.","journal-title":"Sci Transl Med."},{"issue":"1","key":"5895_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12936-015-0618-2","volume":"14","author":"C Chaccour","year":"2015","unstructured":"Chaccour C, Barrio \u00c1I, Royo AGG, Urbistondo DM, Slater H, Hammann F, et al. Screening for an ivermectin slow-release formulation suitable for malaria vector control. Malar J. 2015;14(1):102.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05895-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:34:24Z","timestamp":1779208464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05895-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5895"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05895-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"217"}}